B. Juzyna

发表

Handling informative dropout in longitudinal analysis of health-related quality of life: application of three approaches to data from the esophageal cancer clinical trial PRODIGE 5/ACCORD 17

T. Conroy, C. Touraine, C. Mollevi, 2020, BMC Medical Research Methodology.

Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial.

V. Boige, S. Gourgou-Bourgade, J. Gérard, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy.

T. Conroy, S. Gourgou-Bourgade, M. Jarlier, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

T. Conroy, Y. Bécouarn, O. Bouché, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer

T. Conroy, Y. Bécouarn, O. Bouché, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of single‐nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD‐12/PRODIGE‐2 phase III trial

P. Laurent-Puig, V. Boige, J. Gérard, 2019, International journal of cancer.

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.

M. Pocard, D. Elias, D. Pezet, 2021, The Lancet. Oncology.

Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial.

J. Pignon, T. Conroy, E. Deutsch, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Flexible modeling of longitudinal health-related quality of life data accounting for informative dropout in a cancer clinical trial

S. Gourgou, C. Touraine, C. Mollevi, 2022, Quality of Life Research.

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

T. Conroy, C. Borg, V. Boige, 2020, Journal of Clinical Oncology.

Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial.

J. Pignon, T. Conroy, M. Ducreux, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial.

J. Pignon, T. Conroy, E. Deutsch, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Development of a Clinical–Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial

T. Conroy, J. Salleron, A. Ayav, 2022, Cancers.

Influence of age on chemoradiotherapy outcome in patients with rectal cancer: Exploratory analysis from the phase III study ACCORD 12/0405 PRODIGE 2.

T. Conroy, S. Gourgou-Bourgade, C. Hennequin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03.

M. Sablin, C. Bellera, F. Peyrade, 2017, Oncotarget.

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Lecomte, Sophie Gourgou, T. Conroy, 2018, The New England journal of medicine.

When a joint model should be preferred over a linear mixed model for analysis of longitudinal health-related quality of life data in cancer clinical trials

S. Gourgou, C. Touraine, C. Mollevi, 2023, BMC Medical Research Methodology.

Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in veterans.

P. Polak, T. Fojo, S. Bates, 2021, Seminars in oncology.

Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results

B. Chauffert, T. Conroy, C. Bascoul-Mollevi, 2020, Quality of Life Research.

Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4)

T. Conroy, M. Ychou, O. Bouché, 2017, Oncology.

Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.

E. Assenat, A. Bertaut, F. Bonnetain, 2017 .

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

T. Conroy, J. Douillard, V. Boige, 2014, The Lancet. Oncology.

T. Conroy, C. Bascoul-Mollevi, J. Douillard, 2017, European journal of cancer.

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

T. Conroy, J. Bosset, C. Borg, 2021, The Lancet. Oncology.

Applying the Longitudinal Model from Item Response Theory to Assess Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial

C. Lavergne, T. Conroy, C. Bascoul-Mollevi, 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

Reply to R. Glynne-Jones et al.

T. Conroy, M. Ducreux, D. Peiffert, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA29Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial

E. Assenat, A. Bertaut, F. Bonnetain, 2017 .

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis.

C. Bascoul-Mollevi, C. Borg, S. Gourgou, 2023, European journal of cancer.

Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials

T. Conroy, S. Gourgou, C. Touraine, 2021, Quality of Life Research.

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial.

J. Pignon, T. Conroy, Y. Bécouarn, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.